文献速递核素与放射性配体治疗放射性药物与辐射防护

[177Lu]Lu-DOTATATE的外渗频率:来自365例患者1314个治疗周期的单中心分析

Extravasation Frequency of [177Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients-A Single-Site Analysis.
PubMed 文献 · J Nucl Med · 2025-08-01

本研究回顾性分析单中心365例门诊患者接受[177Lu]Lu-DOTATATE静脉给药共1314个周期的外渗事件,通过注射后3-4小时全身平面显像评估。14例(1.1%)出现提示外渗的输注部位摄取增高,外渗组与对照组外渗活度占给药活度分别为0.07%和0.01%(P<0.001),外渗组外渗吸收剂量中位数0.14 Gy高于对照组0.02 Gy(P<0.001),未观察到放射性组织反应。作者认为外渗罕见且剂量学影响微小,吸收剂量远低于确定性效应和软组织坏死阈值。

要点

  • 1314个给药周期中14例(1.1%)出现提示外渗的输注部位摄取增高。
  • 外渗组与对照组外渗活度占给药活度分别为0.07%和0.01%(P<0.001)。
  • 未观察到任何放射性组织反应,输注部位吸收剂量远低于确定性效应阈值。

核心结论

  • [177Lu]Lu-DOTATATE治疗期间外渗罕见且剂量学后果微小,输注部位吸收剂量远低于确定性效应和软组织坏死阈值。
  • 这些发现表明外渗在该患者队列中对疗效和患者安全的影响可忽略,支持[177Lu]Lu-DOTATATE给药方案的安全性。

研究设计与样本

  • 单中心回顾性分析,365例门诊患者共接受1314个周期[177Lu]Lu-DOTATATE静脉给药,按标准肽受体放射性核素治疗流程给药。
  • 注射后3-4小时行全身平面显像确认给药并评估外渗,以输注部位局灶性摄取增高为外渗指征。
  • 由核医学医师或技师进行定性图像审核标记潜在外渗,对标记病例在输注侧手臂、对侧手臂及大腿勾画感兴趣区,相对于注射活度和全身活度定量外渗活度。
  • 采用MIRD形式体系计算吸收剂量,假设单指数清除模型,并考虑2至7 mm的浸润深度及不同外渗体积。
  • 统计分析比较外渗组与对照组的滞留活度和剂量学参数。

主要发现

  • 1314次给药中14例(1.1%)出现输注部位摄取增高,提示外渗。
  • 输注部位最大放射性药物滞留量小于总注射活度的1%,小于全身活度的2.1%(考虑膀胱排空)。
  • 外渗组与对照组外渗活度占给药活度分别为0.07%和0.01%(P<0.001)。
  • 外渗组输注部位吸收剂量估计中位数0.53 Gy(范围0.12-1.23 Gy) vs 对照组0.32 Gy(范围0.17-0.71 Gy),P=0.3。
  • 外渗组外渗吸收剂量中位数0.14 Gy(范围0.03-0.67 Gy) vs 对照组0.02 Gy(范围0.0-0.19 Gy),P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extravasation of radiopharmaceuticals raises potential concerns, including adverse tissue reactions and reduction in both quantitative accuracy and therapeutic efficacy. This study presents a single-center experience reviewing extravasation events during [177Lu]Lu-DOTATATE administration in peptide receptor radionuclide therapy, assessing their frequency, impact on patient care, and dosimetric effects. Methods: [177Lu]Lu-DOTATATE was administered intravenously to outpatients following standard peptide receptor radionuclide therapy protocols. Whole-body planar imaging was performed 3-4 h after injection to confirm administration and assess extravasation, indicated by focal increased uptake at the infusion site. Qualitative image reviews by nuclear medicine physicians or technologists flagged potential extravasations. For these cases, regions of interest were delineated over the infused and contralateral arm and on the thighs. Extravasated activity was quantified relative to injected and whole-body activity. Absorbed dose calculations were performed using the MIRD formalism, assuming a monoexponential clearance model and accounting for varying extravasate volumes, with infiltration depths ranging from 2 to 7 mm. Statistical analyses compared retained activity and dosimetric parameters between extravasation and control groups. Results: Among 1,314 administrations in 365 outpatients, 14 cases (1.1%) had increased uptake at the infusion site, suggesting extravasation. The maximum radiopharmaceutical retention at the infused site was less than 1% of total injected activity and less than 2.1% whole-body activity (accounting for bladder voiding). The corresponding extravasated activity related to administered activity was 0.07% and 0.01% in the extravasation and control groups, respectively (P < 0.001). The extravasation group had higher absorbed dose estimates at the infusion site than did the control group (median, 0.53 Gy [range, 0.12-1.23 Gy] vs. 0.32 Gy [range, 0.17-0.71 Gy]; P = 0.3), with a significantly higher median extravasated dose (0.14 Gy [range, 0.03-0.67 Gy] vs. 0.02 Gy [range, 0.0-0.19 Gy]; P < 0.001). We did not observe any radiogenic tissue reactions. Conclusion: Extravasation during [177Lu]Lu-DOTATATE therapy was rare and resulted in minimal dosimetric consequences, with absorbed doses at the infusion site well below the thresholds for deterministic effects and soft-tissue necrosis. These findings indicate that extravasation had a negligible impact on treatment efficacy and patient safety in this patient cohort, reinforcing the safety of [177Lu]Lu-DOTATATE administration protocols and emphasizing the low clinical risk associated with radiopharmaceutical extravasation during therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kayal G, Augensen F, Bodei L, et al. Extravasation Frequency of [177Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients-A Single-Site Analysis. J Nucl Med. 2025. PMID: 40571351. doi:10.2967/jnumed.124.269411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。